Vimarsana
Biggest News Aggregation in the World

Page 2 - Pathol Lab News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Pathol Lab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Pathol Lab Today - Breaking & Trending Today

Daiichi Sankyo Company, Limited: ENHERTU Reduced the Risk of Disease Progression or Death by 50% vs. Chemotherapy in Patients with HER2 Low Metastatic Breast Cancer with HR Positive and HR Negative Disease - Vimarsana News

Daiichi Sankyo Company, Limited: ENHERTU Reduced the Risk of Disease Progression or Death by 50% vs. Chemotherapy in Patients with HER2 Low Metastatic Breast Cancer with HR Positive and HR Negative Disease

Daiichi Sankyo and AstraZeneca's ENHERTU also improved median overall survival by more than 6 months vs. chemotherapy in all patients evaluated in DESTINY-Breast04 ENHERTU met the primary

ENHERTU® (fam-trastuzumab deruxtecan-nxki) Reduced the Risk of Disease Progression or Death by 50% vs. Chemotherapy in Patients with HER2-Low Metastatic Breast Cancer with HR-Positive and HR-Negative Disease - Vimarsana News

ENHERTU® (fam-trastuzumab deruxtecan-nxki) Reduced the Risk of Disease Progression or Death by 50% vs. Chemotherapy in Patients with HER2-Low Metastatic Breast Cancer with HR-Positive and HR-Negative Disease

WILMINGTON, Del.--(BUSINESS WIRE)--Jun 5, 2022--

Enhertu granted Breakthrough Therapy Designation in the US for patients with HER2-low metastatic breast cancer - Vimarsana News

Enhertu granted Breakthrough Therapy Designation in the US for patients with HER2-low metastatic breast cancer

AstraZeneca and Daiichi Sankyo’s Enhertu has been granted Breakthrough Therapy Designation in the US for the treatment of adult patients with unresectable or...

Perinatal Deaths From COVID Show 'Extensive' Placental Damage - Vimarsana News

Perinatal Deaths From COVID Show 'Extensive' Placental Damage

Researchers stress the importance of vaccination for pregnant women to avoid catastrophic outcomes of childbirth.

Frontiers | COVID-19 in 28-Week Triplets Caused by Intrauterine Transmission of SARS-CoV-2—Case Report - Vimarsana News

Frontiers | COVID-19 in 28-Week Triplets Caused by Intrauterine Transmission of SARS-CoV-2—Case Report

Since the beginning of the COVID-19 pandemic, in-utero transmission of SARS-CoV-2 remains a rarity and only very few cases have been proven across the world. Here we depict the clinical, laboratory and radiologic findings of preterm triplets born at 28 6/7 weeks to a mother who contracted COVID-19 just one week before delivery. The triplets showed SARS-CoV-2 positivity right after birth, developed significant leukopenia and early-onset pulmonary interstitial emphysema. The most severely affected triplet I required ten days of high-frequency oscillatory ventilation due to failure of conventiona...